Stem Cell Therapy in Chronic Ischemic Heart Dysfunction with and Without Viability
Pedro L. Sanchez,
M. Eugenia Fernandez-Santos,
M. Jose Lorenzo,
A growing number of clinical trials are evaluating the effects of stem cell therapy in patients with chronic ischemic heart dysfunction. As most of the clinical trials included a limited and different number of patients, various stem cell sources and several delivery approaches, results vary substantially between these studies. We analyse whether the assessment of myocardial viability may be important when evaluating effects of stem cell transplantation on parameters of left ventricular remodeling. Viability assessment could help to find the best type of stem cell and the best method of cell delivery to be used in chronic ischemic heart dysfunction.
Keywords: Stem cell, ischemic heart disease, viability, left ventricular function, coronary artery bypass graft surgery, CABG, single-photon emission computed tomography, SPECT, positron emission tomo- graphy, PET, magnetic resonce imaging, MRI, Echocardiography, left ventricle ejection fraction, LVEF, plasticity, Skeletal myoblasts, myocardial contractility, Adipose-derived stem cells, circulating progenitor cells, CPC, granulocyte colony, G-CSF, MAGIC Cell-3-DES, bone marrow mononuclear cells, BMMC, TOPCARE-CHD trial, NOGA electromechanical mapping, PROTECT-CAD trial
Rights & PermissionsPrintExport